Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
Date:5/2/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the launch of an educational campaign designed to provide healthcare professionals (HCPs) with a greater understanding of the role sodium glucose co-transporters (SGLTs) play in maintaining blood sugar balance, or glucose homeostasis.1

The SGLT disease education initiative features the microsite www.SGLT.com and a short dynamic educational video, Glucose Perspectives, in the form of sketch animation by the Royal Society for the encouragement of Arts, Manufactures and Commerce (RSA). Additional learning options will be offered throughout the year for HCPs to learn more about SGLTs and their role in glucose homeostasis.

A chronic condition, type 2 diabetes mellitus (T2D) is characterized by persistent high blood sugar levels (hyperglycemia).2 The inability to maintain normal blood sugar balance is due either to an inability to respond properly to the hormone insulin, also known as insulin resistance, or to inadequate amounts of insulin in the body as a result of impaired beta-cell function, or a combination of the two.

SGLTs act to ensure glucose entering the kidneys finds its way back into the bloodstream instead of being passed in the urine.3 Nearly all of the filtered glucose is reabsorbed in the kidneys by sodium glucose co-transporters 1 and 2, with SGLT2 accounting for about 90 percent of this re-absorption. 3

In people with T2D, persistent hyperglycemia can lead to increased re-absorption of glucose through SGLT2.1 This means more glucose is being reabsorbed into the blood in a continuous action, which perpetuates hyperglycemia a
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
4. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
5. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
6. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
7. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
8. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
9. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
10. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
11. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive ... helped cut the rate of infection with a dangerous ... percent. Clostridium difficile, or C.diff, is a ... life-threatening inflammation of the colon. A recent article in ... Clostridium difficile Infection in the United States ...
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)... 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... it acquired Bionik Laboratories, Inc., a Toronto ... to qualified accredited investors of units consisting of its ... approximately $6.2 million. Shares of the Company,s common stock ... under the symbol "DWTPD" until FINRA,s approval of the ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... West Pharmaceutical Services, Inc. (NYSE: WST ) today ...  Summary comparative results were as follows: ($ millions, except per-share ... $ 281.8Gross Profit , 84.6 , 83.2Reported Operating Profit , ... 30.5 , 30.9Reported Diluted EPS , $ 0.57 , $ ...
... SEATTLE, July 28, 2011 Cell Therapeutics, Inc. ("CTI" or ... its efforts to develop its late stage oncology pipeline to ... ended June 30, 2011. "In the second quarter, ... the FDA,s Office of New Drugs ("OND") in allowing us ...
Cached Medicine Technology:West Announces Second Quarter 2011 Results 2West Announces Second Quarter 2011 Results 3West Announces Second Quarter 2011 Results 4West Announces Second Quarter 2011 Results 5West Announces Second Quarter 2011 Results 6West Announces Second Quarter 2011 Results 7West Announces Second Quarter 2011 Results 8West Announces Second Quarter 2011 Results 9West Announces Second Quarter 2011 Results 10West Announces Second Quarter 2011 Results 11West Announces Second Quarter 2011 Results 12West Announces Second Quarter 2011 Results 13West Announces Second Quarter 2011 Results 14West Announces Second Quarter 2011 Results 15West Announces Second Quarter 2011 Results 16Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 2Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 3Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 4Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 5Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 6
(Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
(Date:2/28/2015)... Ohio (PRWEB) February 28, 2015 ... Motivational? Supportive? Strategic? , There are all kinds ... strengths. To raise awareness of the advantages and ... firm PeopleKeys is launching a new product this ... clients better understand the connection between personality type, ...
(Date:2/28/2015)... The noted Friedman Dental Group of South ... relaunched their website. The new version of the site ... new section about their team members. Potential and current ... of each Friedman Dental Group team member including new ... to provide our patients with the opportunity to get ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as ... at the latest and coolest technology products and services available ... a technology expert, conducted the review and shared with viewers ... Getting stuck with a low battery and no way to ... face on a daily basis. Even when a person does ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2
... A major research company with expertise in managing clinical ... Medical Campus to more efficiently bring the latest stem ... formally known as the Colorado Prevention Center, officially moved ... from the campus on Friday., It is the ...
... poor judges of their patients, health beliefs, according to ... A&M University and Paul Haidet from The Pennsylvania State ... is better the more patients are involved by asking ... for care. Their analysis 1 of how ...
... undergo cardiopulmonary bypass (CPB) during surgery for less ... suffer any impairments in neurocognitive abilities, such as ... Researchers from The Children,s Hospital of Philadelphia, in ... Pediatrics , reported on neuropsychological effects after surgery ...
... , , , , ... AUDIO: Scientists at Washington University School of Medicine in St. ... Click here for more information. , , ... , , , , , , ...
... Gardner HealthDay Reporter , THURSDAY, July 22 (HealthDay ... favorite pastimes -- sitting around -- the shorter their average ... remained even after researchers factored out obesity or the level ... a study of more than 120,000 American adults. It,s ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... face a greater risk of having a stillborn child if ... treatments, a new study finds. Although neither boys nor ... that might affect their offspring, radiation damage to the uterus ...
Cached Medicine News:Health News:University of Colorado joins with major research firm to partner on stem cell research 2Health News:Doctors don't 'get' their patients 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 3Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 4Health News:The Longer You Sit, the Shorter Your Life Span: Study 2Health News:Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later 2Health News:Radiation for Childhood Cancer Can Boost Risk of Stillbirth Later 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: